Ucb Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for UCB INC, and when can generic versions of UCB INC drugs launch?
UCB INC has forty-two approved drugs.
There are thirty-four US patents protecting UCB INC drugs.
There are four hundred and seventy-seven patent family members on UCB INC drugs in fifty-one countries and thirty-nine supplementary protection certificates in fourteen countries.
Summary for Ucb Inc
International Patents: | 477 |
US Patents: | 34 |
Tradenames: | 29 |
Ingredients: | 24 |
NDAs: | 42 |
Drug Master File Entries: | 1 |
Patent Litigation for Ucb Inc: | See patent lawsuits for Ucb Inc |
Drugs and US Patents for Ucb Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ucb Inc | FINTEPLA | fenfluramine hydrochloride | SOLUTION;ORAL | 212102-001 | Jun 25, 2020 | RX | Yes | Yes | 10,478,441*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Ucb Inc | ZILBRYSQ | zilucoplan sodium | SOLUTION;SUBCUTANEOUS | 216834-002 | Oct 17, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Ucb Inc | FLUXID | famotidine | TABLET, ORALLY DISINTEGRATING;ORAL | 021712-001 | Sep 24, 2004 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Ucb Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Ucb Inc | VIMPAT | lacosamide | TABLET;ORAL | 022253-002 | Oct 28, 2008 | 5,654,301 | ⤷ Try a Trial |
Ucb Inc | NEUPRO | rotigotine | FILM, EXTENDED RELEASE;TRANSDERMAL | 021829-006 | Apr 2, 2012 | 6,699,498 | ⤷ Try a Trial |
Ucb Inc | KEPPRA XR | levetiracetam | TABLET, EXTENDED RELEASE;ORAL | 022285-001 | Sep 12, 2008 | 4,943,639*PED | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for UCB INC drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Oral Solution | 10 mg/mL | ➤ Subscribe | 2012-10-29 |
➤ Subscribe | Injection | 10 mg/mL, 20 mL | ➤ Subscribe | 2016-06-30 |
➤ Subscribe | Orally Disintegrating Tablets | 0.25 mg, 0.5 mg, 1 mg and 2 mg | ➤ Subscribe | 2005-12-27 |
➤ Subscribe | Tablets | 1000 mg | ➤ Subscribe | 2007-01-24 |
➤ Subscribe | Tablets | 50 mg, 100 mg, 150 mg, and 200 mg | ➤ Subscribe | 2012-10-29 |
➤ Subscribe | Extended-release Tablets | 1000 mg | ➤ Subscribe | 2011-01-07 |
➤ Subscribe | Tablets | 7.5mg/12.5mg 15 mg/25 mg and 15 mg/12.5 mg | ➤ Subscribe | 2004-01-15 |
➤ Subscribe | Extended-release Transdermal Film | 1 mg/24 hr, 2 mg/24 hr, 3 mg/24 hr,4 mg/24 hr,6 mg/24 hr, and 8 mg/24 hr | ➤ Subscribe | 2013-11-26 |
International Patents for Ucb Inc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Norway | 3092234 | ⤷ Try a Trial |
Israel | 170181 | ⤷ Try a Trial |
Canada | 2595988 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Ucb Inc Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1265862 | PA2016013,C1265862 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: BRIVARACETAMAS; REGISTRATION NO/DATE: EU/1/15/1073 20160114 |
1033978 | 06C0025 | France | ⤷ Try a Trial | PRODUCT NAME: ROTIGOTINE; REGISTRATION NO/DATE: EU/1/05/331/001 20060215 |
1033978 | CA 2006 00020 | Denmark | ⤷ Try a Trial | PRODUCT NAME: ROTIGOTINE |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.